Next Article in Journal
Effectiveness of COVID-19 Vaccines: Evidence from the First-Year Rollout of Vaccination Programs
Next Article in Special Issue
Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients
Previous Article in Journal
Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19
Previous Article in Special Issue
A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 3
10.3390/vaccines10030408
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System

by
Kathleen Gallo
1,
Andrean Goede
1,
Cameron Mura
2,
Renata Abel
1,
Barbara Moahamed
1,
Saskia Preissner
3,
Susanne Nahles
3,
Max Heiland
3,
Philip E. Bourne
2,
Robert Preissner
1,* and
Michael Mallach
1
1
Institute of Physiology and Science IT, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, 10117 Berlin, Germany
2
School of Data Science and Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22904, USA
3
Department of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Humboldt-Universität zu Berlin, 10117 Berlin, Germany
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(3), 408; https://doi.org/10.3390/vaccines10030408
Submission received: 27 January 2022 / Revised: 23 February 2022 / Accepted: 4 March 2022 / Published: 8 March 2022
(This article belongs to the Special Issue Big Data Analytics in Pandemic)
Browse Figures
Versions Notes

Abstract

Background: The COVID-19 pandemic is being battled via the largest vaccination campaign in history, with more than eight billion doses administered thus far. Therefore, discussions about potentially adverse reactions, and broader safety concerns, are critical. The U.S. Vaccination Adverse Event Reporting System (VAERS) has recorded vaccination side effects for over 30 years. About 580,000 events have been filed for COVID-19 thus far, primarily for the Johnson & Johnson (New Jersey, USA), Pfizer/BioNTech (Mainz, Germany), and Moderna (Cambridge, USA) vaccines. Methods: Using available databases, we evaluated these three vaccines in terms of the occurrence of four generally-noticed adverse reactions—namely, cerebral venous sinus thrombosis, Guillain–Barré syndrome (a severe paralytic neuropathy), myocarditis, and pericarditis. Our statistical analysis also included a calculation of odds ratios (ORs) based on total vaccination numbers, accounting for incidence rates in the general population. Results: ORs for a number of adverse events and patient groups were (largely) increased, most notably for the occurrence of cerebral venous sinus thrombosis after vaccination with the Johnson & Johnson vaccine. The overall population OR of 10 increases to 12.5 when limited to women, and further yet (to 14.4) among women below age 50 yrs. In addition, elevated risks were found (i) for Guillain–Barré syndrome (OR of 11.6) and (ii) for myocarditis/pericarditis (ORs of 5.3/4.1, respectively) among young men (<25 yrs) vaccinated with the Pfizer/BioNTech vaccine. Conclusions: Any conclusions from such a retrospective, real-world data analysis must be drawn cautiously, and should be confirmed by prospective double-blinded clinical trials. In addition, we emphasize that the adverse events reported here are not specific side effects of COVID vaccines, and the significant, well-established benefits of COVID-19 vaccination outweigh the potential complications surveyed here.
Keywords: COVID-19; vaccine safety; real-world evidence; carditis; thrombosis; Guillain–Barré syndrome COVID-19; vaccine safety; real-world evidence; carditis; thrombosis; Guillain–Barré syndrome

Share and Cite

MDPI and ACS Style

Gallo, K.; Goede, A.; Mura, C.; Abel, R.; Moahamed, B.; Preissner, S.; Nahles, S.; Heiland, M.; Bourne, P.E.; Preissner, R.; et al. A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System. Vaccines 2022, 10, 408. https://doi.org/10.3390/vaccines10030408

AMA Style

Gallo K, Goede A, Mura C, Abel R, Moahamed B, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R, et al. A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System. Vaccines. 2022; 10(3):408. https://doi.org/10.3390/vaccines10030408

Chicago/Turabian Style

Gallo, Kathleen, Andrean Goede, Cameron Mura, Renata Abel, Barbara Moahamed, Saskia Preissner, Susanne Nahles, Max Heiland, Philip E. Bourne, Robert Preissner, and et al. 2022. "A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System" Vaccines 10, no. 3: 408. https://doi.org/10.3390/vaccines10030408

APA Style

Gallo, K., Goede, A., Mura, C., Abel, R., Moahamed, B., Preissner, S., Nahles, S., Heiland, M., Bourne, P. E., Preissner, R., & Mallach, M. (2022). A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System. Vaccines, 10(3), 408. https://doi.org/10.3390/vaccines10030408

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop